BioSpace News Archive

The global stem cell therapy market size was estimated at USD 11.22 billion in 2022 and it is projected to reach around USD 31.41 billion by 2030 and growing at a compound annual growth rate (CAGR) of 13.73% during the forecast period 2023 to 2030.

Oxford Nanopore Technologies plc and Geneyx, an AI platform for human genetic analysis and interpretation, are aiming to team up to develop the first scalable software solution for the end-to-end analysis and clinical reporting of nanopore sequencing data.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn”) a biotechnology company developing therapeutics targeting addiction, with a near term focus on Alcohol Use Disorder

Phathom Pharmaceuticals, Inc. announced the closing of the sale of an additional 1,668,750 shares of common stock at a public offering price of $11.75 per share pursuant to the exercise in full of the underwriters’ option to purchase additional shares in connection with Phathom’s recently completed public offering.

Cogent Biosciences, Inc., a biotechnology company focused on developing precision therapies for genetically defined diseases, announced the closing of its previously announced upsized underwritten public offering of 12,500,000 shares of its common stock.

Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, announced that it will release financial results for the third quarter of fiscal year 2023 ended March 31, 2023, before the market open on Monday, June 12, 2023.

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted two new employees options to purchase a total of 11,600 shares of the Company’s common stock at an exercise price per share of $21.64, which was the closing price on June 8, 2023, and restricted stock units to acquire a total of 5,800 shares of the Company’s common stock.

Labcorp, a leading global life sciences company, announced the following record and distribution dates for the spin-off of Fortrea Holdings Inc., a wholly owned subsidiary of Labcorp.

Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced it will present data from the Phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A in patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL) in an oral presentation at the International Conference on Malignant Lymphoma (ICML) on June 13–17, 2023.